Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 13, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	320	247	200	179	191	329
Market Cap Growth	-71.57%	23.61%	11.79%	-6.49%	-41.88%	-
Enterprise Value	164	49	110	60	119	233
Last Close Price	3.70	3.87	4.55	4.13	10.79	21.41
PB Ratio	1.64	1.44	2.44	1.61	2.97	3.67
P/TBV Ratio	2.20	1.44	2.44	1.61	2.97	3.67
Debt / Equity Ratio	0.03	0.03	0.07	0.05	0.09	0.07
Quick Ratio	7.17	7.58	9.16	11.06	7.95	10.31
Current Ratio	7.48	8.02	9.49	11.28	8.16	10.89
Return on Equity (ROE)	-50.77%	-63.59%	-38.36%	-40.33%	-65.72%	-95.47%
Return on Assets (ROA)	-31.47%	-38.36%	-23.48%	-22.26%	-34.40%	-48.69%
Return on Capital (ROIC)	-34.17%	-43.00%	-25.64%	-24.45%	-37.86%	-55.96%
Earnings Yield	-30.07%	-32.64%	-18.50%	-19.78%	-26.50%	-12.92%
FCF Yield	-27.62%	-28.86%	-16.83%	-15.48%	-22.21%	-12.85%
Buyback Yield / Dilution	-37.88%	-39.53%	-70.42%	-50.09%	-44.44%	-95.09%

Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q